Pub Date : 2017-02-13DOI: 10.4172/2329-6917.1000225
Selvi Rahmawati, S. Fatmawati, Stefanus Purwanto, Eugeu Yasmin, Susan Simanjaya, S. Hutajulu, D. K. Paramita
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder of hematopoietic , characterized by Philadelphia chromosome containing BCR-ABL fusion gene. The gene encodes protein with constitutive tyrosine kinase activity result in myeloid proliferation and leads to form an early phase of CML called chronic phase. Unsuccessful treatment will lead to progression of the disease into late phase (accelerated and blast crisis). The mechanisms involving disease progression are still poorly understood. It is assumed that additional genetic event involves in differentiation blocking of myeloid progenitor cells, such as Hes-1 overexpression and CEBPA down regulation. However, study on the expression of these genes in CML patient’s samples is still limited. This study aims to measure Hes-1 and CEBPA mRNA in chronic and late phase of CML patients. The peripheral blood mRNA level of Hes-1 was measured in CML patient’s sample with BCR-ABL positive both in chronic phase (n=61) and late phase (n=17) using qRT-PCR with GAPDH as internal control. Hes-1 mRNA was statistically higher (p value=0.0) in the chronic phase (mean ± SD=97.8 ± 236.6) compared to those in late phase (mean ± SD=8.5 ± 30.7). In addition, even though CEBPA expression in chronic and late phase were not statistically different (p value=0.1), those in chronic phase (mean ± SD=5.2 ± 16.0) were generally higher compared to those in late phase (mean ± SD=1.7 ± 2.4). Hes-1 expression upregulated in 70.5% of chronic phase patients and in 17.6% of late phase patients, whereas CEBPA expression down regulated in 42.6% of chronic phase patients and in 47.1% in late phase patients. High standard deviation, particularly in mRNA Hes-1 gene expression measurement of the chronic phase, indicated the presence of individual variations in the sample that might be influenced by other genetic factors. This study found that Hes-1 mRNA is significantly higher in peripheral blood of chronic phase than blast crisis CML, whereas CEBPA mRNA is not different.
{"title":"HES-1 and CEBPA mRNA in Chronic and Late Phase (accelerated and blast crisis) of Chronic Myeloid Leukemia (CML) Patients","authors":"Selvi Rahmawati, S. Fatmawati, Stefanus Purwanto, Eugeu Yasmin, Susan Simanjaya, S. Hutajulu, D. K. Paramita","doi":"10.4172/2329-6917.1000225","DOIUrl":"https://doi.org/10.4172/2329-6917.1000225","url":null,"abstract":"Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder of hematopoietic , characterized by Philadelphia chromosome containing BCR-ABL fusion gene. The gene encodes protein with constitutive tyrosine kinase activity \u0000 result in myeloid proliferation and leads to form an early phase of CML called chronic phase. Unsuccessful treatment \u0000 will lead to progression of the disease into late phase (accelerated and blast crisis). The mechanisms involving \u0000 disease progression are still poorly understood. It is assumed that additional genetic event involves in differentiation \u0000 blocking of myeloid progenitor cells, such as Hes-1 overexpression and CEBPA down regulation. However, study on \u0000 the expression of these genes in CML patient’s samples is still limited. This study aims to measure Hes-1 and \u0000 CEBPA mRNA in chronic and late phase of CML patients. The peripheral blood mRNA level of Hes-1 was measured \u0000 in CML patient’s sample with BCR-ABL positive both in chronic phase (n=61) and late phase (n=17) using qRT-PCR \u0000 with GAPDH as internal control. Hes-1 mRNA was statistically higher (p value=0.0) in the chronic phase (mean ± \u0000 SD=97.8 ± 236.6) compared to those in late phase (mean ± SD=8.5 ± 30.7). In addition, even though CEBPA \u0000 expression in chronic and late phase were not statistically different (p value=0.1), those in chronic phase (mean ± \u0000 SD=5.2 ± 16.0) were generally higher compared to those in late phase (mean ± SD=1.7 ± 2.4). Hes-1 expression \u0000 upregulated in 70.5% of chronic phase patients and in 17.6% of late phase patients, whereas CEBPA expression \u0000 down regulated in 42.6% of chronic phase patients and in 47.1% in late phase patients. High standard deviation, \u0000 particularly in mRNA Hes-1 gene expression measurement of the chronic phase, indicated the presence of individual \u0000 variations in the sample that might be influenced by other genetic factors. This study found that Hes-1 mRNA is \u0000 significantly higher in peripheral blood of chronic phase than blast crisis CML, whereas CEBPA mRNA is not \u0000 different.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"5 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-02DOI: 10.4172/2329-6917.1000E120
C. Corrado
From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistant mutants of BCR-ABL[4].
{"title":"Chronic Myelogenous Leukemia: Approaches to Pharmacological Resistance","authors":"C. Corrado","doi":"10.4172/2329-6917.1000E120","DOIUrl":"https://doi.org/10.4172/2329-6917.1000E120","url":null,"abstract":"From 2000 some data relative to IM resistance were available. There are many mechanisms responsible of IM resistance, more often point mutations that cause the progression to blast crisis and death in few months. To circumvent them, more potent TKIs have been subsequently approved [3]. However, another problem arise: these compounds don’t work on all patients because of the different IMresistant mutants of BCR-ABL[4].","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":" ","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48475527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mycobacterium tuberculosis (TB) is not uncommon in immunocompromised patients. TB is often neglected because of its atypical manifestation, especially in the early stages of disease. Although some leukemic patients are complicated with co-presentation of TB during their immunosuppressed stage, the advent of miliary pulmonary TB is seldom reported. Herein, we describe a case of active TB in a 6-year-old male with acute lymphoblastic leukemia during the late maintenance phase of therapy. He developed acute miliary pulmonary TB within two weeks after initial signs of lung presentation. The patient recovered in two months by anti-TB treatment of four co-administered therapies
{"title":"Rapid Onset of Acute Miliary Pulmonary Tuberculosis in a Child with AcuteLymphoblastic Leukemia","authors":"C. Jia, Ruidong Zhang, Shunying Zhao, Yuanyuan Zhang, Ying Wu, Jia Fan, Huyong Zheng","doi":"10.4172/2329-6917.1000224","DOIUrl":"https://doi.org/10.4172/2329-6917.1000224","url":null,"abstract":"Mycobacterium tuberculosis (TB) is not uncommon in immunocompromised patients. TB is often neglected because of its atypical manifestation, especially in the early stages of disease. Although some leukemic patients are complicated with co-presentation of TB during their immunosuppressed stage, the advent of miliary pulmonary TB is seldom reported. Herein, we describe a case of active TB in a 6-year-old male with acute lymphoblastic leukemia during the late maintenance phase of therapy. He developed acute miliary pulmonary TB within two weeks after initial signs of lung presentation. The patient recovered in two months by anti-TB treatment of four co-administered therapies","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":" ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44379007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000241
Rita Nader, E. Saad, V. Najjar, Annoir Shayya, Y. Comair, H. Ghanem
Primary Bone Lymphoma of the skull is extremely rare and has a variable clinical course and prognosis. We are describing a case of a 26 year old woman who presented with a 2 year history of intermittent scalp swelling and skull pain. Brain MRI showed thickening of the bilateral frontal bones and band thickening of the underlying meninges suggestive of band meningiomatosis. Patient was presumably diagnosed with a meningioma based on radiological findings and underwent resection; however, pathology was consistent with a B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. A PET CT scan showed sacral bone hypermetabolic lesion which was biopsied and consistent with same lymphoma features. She received chemotherapy with Rituximab and Hyper-CVAD protocol (Table 1) and had a sustained ongoing complete remission 19 months after her initial diagnosis. Several cases of primary lymphoma of the skull or cranial vault have been described in the literature, but only one other case with the same pathology of Burkittlike lymphoma was found.
{"title":"Primary Bone Burkitt’s like Lymphoma of the Skull Mimicking Meningioma-Case Report and Review of Literature","authors":"Rita Nader, E. Saad, V. Najjar, Annoir Shayya, Y. Comair, H. Ghanem","doi":"10.4172/2329-6917.1000241","DOIUrl":"https://doi.org/10.4172/2329-6917.1000241","url":null,"abstract":"Primary Bone Lymphoma of the skull is extremely rare and has a variable clinical course and prognosis. We are describing a case of a 26 year old woman who presented with a 2 year history of intermittent scalp swelling and skull pain. Brain MRI showed thickening of the bilateral frontal bones and band thickening of the underlying meninges suggestive of band meningiomatosis. Patient was presumably diagnosed with a meningioma based on radiological findings and underwent resection; however, pathology was consistent with a B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. A PET CT scan showed sacral bone hypermetabolic lesion which was biopsied and consistent with same lymphoma features. She received chemotherapy with Rituximab and Hyper-CVAD protocol (Table 1) and had a sustained ongoing complete remission 19 months after her initial diagnosis. Several cases of primary lymphoma of the skull or cranial vault have been described in the literature, but only one other case with the same pathology of Burkittlike lymphoma was found.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70270022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000E121
F. Socola
CLL is the most prevalent adult leukemia in the western countries with 18,960 new cases diagnosed in 2016 and estimated mortality of 25% per year [1]. It is an extremely heterogeneous disease with the clinical course varying from patients who never require therapy to a rapidly progressive and fatal malignancy in others. While most patients treated with fludarabine, cyclophosphamide and rituximab achieve 3-years OS of 87%, there is a high risk CLL group that has a dismal prognosis with a 4-years OS of less than 20% when they are treated with chemo immunotherapy [2,3]. High risk CLL is defined by presence of non-response or early relapse (within 12 months) after purine analogues, relapse within 24 months after having achieved a response with purine analogue-based combination therapy or autologous transplantation, and patients with p53 mutation or del(17p) requiring treatment. In 2007 the European Group for Bone Marrow Transplantation (EBMT) recommended that patient with high risk disease should be considered for allogeneic stem cell transplant [4].
{"title":"Role of Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia and its Implications in Current Era","authors":"F. Socola","doi":"10.4172/2329-6917.1000E121","DOIUrl":"https://doi.org/10.4172/2329-6917.1000E121","url":null,"abstract":"CLL is the most prevalent adult leukemia in the western countries with 18,960 new cases diagnosed in 2016 and estimated mortality of 25% per year [1]. It is an extremely heterogeneous disease with the clinical course varying from patients who never require therapy to a rapidly progressive and fatal malignancy in others. While most patients treated with fludarabine, cyclophosphamide and rituximab achieve 3-years OS of 87%, there is a high risk CLL group that has a dismal prognosis with a 4-years OS of less than 20% when they are treated with chemo immunotherapy [2,3]. High risk CLL is defined by presence of non-response or early relapse (within 12 months) after purine analogues, relapse within 24 months after having achieved a response with purine analogue-based combination therapy or autologous transplantation, and patients with p53 mutation or del(17p) requiring treatment. In 2007 the European Group for Bone Marrow Transplantation (EBMT) recommended that patient with high risk disease should be considered for allogeneic stem cell transplant [4].","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"5 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000E121","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70270326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000242
Bowen Li, D. Amato, Chen Wang
Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm with characteristic immunophenotype. This report presents a rare case of CLL with co-expression of T-cell marker CD8. The molecular analysis confirmed clonal immunoglobulin genes and no clonal rearrangement for T-cell receptor β and γ genes. The cell morphology was atypical of CLL, with features resembling reactive T lymphocytes. The phenotypic and morphologic findings may represent a CLL variant.
{"title":"Chronic Lymphocytic Leukemia with Aberrant CD8 Expression and Atypical Morphology: A Case Report and Review","authors":"Bowen Li, D. Amato, Chen Wang","doi":"10.4172/2329-6917.1000242","DOIUrl":"https://doi.org/10.4172/2329-6917.1000242","url":null,"abstract":"Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm with characteristic immunophenotype. This report presents a rare case of CLL with co-expression of T-cell marker CD8. The molecular analysis confirmed clonal immunoglobulin genes and no clonal rearrangement for T-cell receptor β and γ genes. The cell morphology was atypical of CLL, with features resembling reactive T lymphocytes. The phenotypic and morphologic findings may represent a CLL variant.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"5 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000242","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70270032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000243
Y. Hashii, Y. Kosaka, Kenichiro Watanabe, Koji Kato, M. Imaizumi, T. Kaneko, S. Sunami, A. Watanabe, H. Hiramatsu, Yuhki Koga, M. Hirayama, T. Nakao, T. Hata, N. Uchida, K. Ishiyama, K. Mitani, M. Hidaka, K. Kitamura, Hiroko Tsunemine, Y. Ueda, A. Mugitani, K. Usuki, Y. Kanda, Y. Miyazaki, K. Imai, T. Naoe, K. Koh, H. Sugiyama, K. Horibe
This study enrolled 49 patients with de novo childhood acute lymphoblastic leukemia (ALL) and 19 adult patients with ALL. WT1 mRNA showed high positive expression rates of 90% or more in ALL patients, and fusion gene transcripts were detected in 22.4% of childhood ALL cases prior to treatment. During follow-up at 4-6 months, WT1 mRNA levels in childhood ALL cases were observed to be lower in patients undergoing hematological remission after treatment when compared to the initial stages. We also assessed hematological remission via ROC analysis. The upper cut-off values were calculated to be 220 and 1,820 copies/μg RNA in the peripheral blood (PB) and bone marrow (BM) samples, respectively. Since 50 copies/μg RNA was determined to be both, the limit of detection (LOD) and minimal residual disease (MRD) threshold, WT1 mRNA regions below the upper cut-off values indicated remission depth. The detection of high WT1 mRNA levels, even in patients without fusion gene transcripts, reflected the treatment effects and remission depth, demonstrating its capacity to be a useful MRD monitoring marker in ALL.
{"title":"Clinical Significance of Wt1 mRNA Levels in Japanese Acute Lymphoblastic Leukemia Patients","authors":"Y. Hashii, Y. Kosaka, Kenichiro Watanabe, Koji Kato, M. Imaizumi, T. Kaneko, S. Sunami, A. Watanabe, H. Hiramatsu, Yuhki Koga, M. Hirayama, T. Nakao, T. Hata, N. Uchida, K. Ishiyama, K. Mitani, M. Hidaka, K. Kitamura, Hiroko Tsunemine, Y. Ueda, A. Mugitani, K. Usuki, Y. Kanda, Y. Miyazaki, K. Imai, T. Naoe, K. Koh, H. Sugiyama, K. Horibe","doi":"10.4172/2329-6917.1000243","DOIUrl":"https://doi.org/10.4172/2329-6917.1000243","url":null,"abstract":"This study enrolled 49 patients with de novo childhood acute lymphoblastic leukemia (ALL) and 19 adult patients with ALL. WT1 mRNA showed high positive expression rates of 90% or more in ALL patients, and fusion gene transcripts were detected in 22.4% of childhood ALL cases prior to treatment. During follow-up at 4-6 months, WT1 mRNA levels in childhood ALL cases were observed to be lower in patients undergoing hematological remission after treatment when compared to the initial stages. We also assessed hematological remission via ROC analysis. The upper cut-off values were calculated to be 220 and 1,820 copies/μg RNA in the peripheral blood (PB) and bone marrow (BM) samples, respectively. Since 50 copies/μg RNA was determined to be both, the limit of detection (LOD) and minimal residual disease (MRD) threshold, WT1 mRNA regions below the upper cut-off values indicated remission depth. The detection of high WT1 mRNA levels, even in patients without fusion gene transcripts, reflected the treatment effects and remission depth, demonstrating its capacity to be a useful MRD monitoring marker in ALL.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"5 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000243","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70270080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000236
S. Abo, C. Granger
Allogeneic bone marrow transplantation (alloBMT) is a highly intensive form of treatment for people with haematological cancer. Given its intensity and potential short and long term complications, there are significant risks of physical and psychological morbidity following treatment [1]. Several studies have identified that the side effects of an alloBMT can be long term and include physical impairments such as muscle weakness and reduced endurance; persistent symptoms such as fatigue; and poor health-related quality of life (HRQoL) [2,3]. Whilst the side effects observed in allogeneic and autologous BMT are similar, those experienced following an alloBMT are more numerous and severe due to prolonged hospital length of stay and greater risk of debilitating long-term complications such as graftversus-host-disease [1,4]. The survival rate for patients treated with alloBMT is increasing [5] and therefore as this chronic disease population increases in size, there is awareness of the need to focus on prevention of long-term morbidity and addressing patient survivorship needs.
同种异体骨髓移植(Allogeneic bone marrow transplantation, alloBMT)是血液学癌症患者的一种高度强化的治疗形式。鉴于其强度和潜在的短期和长期并发症，治疗bbb后存在显著的生理和心理发病率风险。一些研究已经确定同种异体bmt的副作用可能是长期的，包括身体损伤，如肌肉无力和耐力降低;持续性症状，如疲劳;健康相关生活质量(HRQoL)较差[2,3]。虽然同种异体和自体骨髓移植中观察到的副作用相似，但同种异体骨髓移植后的副作用更多、更严重，因为住院时间更长，出现长期并发症(如移植物抗宿主病)的风险更大[1,4]。接受同种异体bmt治疗的患者的生存率正在增加，因此，随着这种慢性疾病人群规模的增加，人们意识到需要关注预防长期发病率和解决患者生存需求。
{"title":"Changing the Way We Approach Rehabilitation in Bone Marrow Transplantation","authors":"S. Abo, C. Granger","doi":"10.4172/2329-6917.1000236","DOIUrl":"https://doi.org/10.4172/2329-6917.1000236","url":null,"abstract":"Allogeneic bone marrow transplantation (alloBMT) is a highly intensive form of treatment for people with haematological cancer. Given its intensity and potential short and long term complications, there are significant risks of physical and psychological morbidity following treatment [1]. Several studies have identified that the side effects of an alloBMT can be long term and include physical impairments such as muscle weakness and reduced endurance; persistent symptoms such as fatigue; and poor health-related quality of life (HRQoL) [2,3]. Whilst the side effects observed in allogeneic and autologous BMT are similar, those experienced following an alloBMT are more numerous and severe due to prolonged hospital length of stay and greater risk of debilitating long-term complications such as graftversus-host-disease [1,4]. The survival rate for patients treated with alloBMT is increasing [5] and therefore as this chronic disease population increases in size, there is awareness of the need to focus on prevention of long-term morbidity and addressing patient survivorship needs.","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"05 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2329-6917.1000237
Tamim Alsuliman, K. Debbache, M. Terrom, E. Maillot, Kaiss Lassouedand Bachra Choufi
Tamim Alsuliman1,2, Karima Debbache1, Maelle Terrom1, Elisabeth Maillot2, Kaiss Lassoued1 and Bachra Choufi1* 1Department of Hematology, Boulogne-sur-Mer Hospital Center, Boulogne-sur-Mer, France 2Department of Hematology, Center Hospitalier Régionale Universitaire, Lille, France 3Cabinet of Anatomy and Pathological Cytology, Saint Omer Cedex *Corresponding author: Bachra Choufi, Department of Hematology, Boulogne-sur-Mer Hospital Center, Boulogne-sur-Mer, France, Tel: 861033520; E-mail: b.choufi@gmail.com
{"title":"Azacitidine Related Pyoderma Gangrenosum","authors":"Tamim Alsuliman, K. Debbache, M. Terrom, E. Maillot, Kaiss Lassouedand Bachra Choufi","doi":"10.4172/2329-6917.1000237","DOIUrl":"https://doi.org/10.4172/2329-6917.1000237","url":null,"abstract":"Tamim Alsuliman1,2, Karima Debbache1, Maelle Terrom1, Elisabeth Maillot2, Kaiss Lassoued1 and Bachra Choufi1* 1Department of Hematology, Boulogne-sur-Mer Hospital Center, Boulogne-sur-Mer, France 2Department of Hematology, Center Hospitalier Régionale Universitaire, Lille, France 3Cabinet of Anatomy and Pathological Cytology, Saint Omer Cedex *Corresponding author: Bachra Choufi, Department of Hematology, Boulogne-sur-Mer Hospital Center, Boulogne-sur-Mer, France, Tel: 861033520; E-mail: b.choufi@gmail.com","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"05 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-25DOI: 10.4172/2329-6917.1000223
Ling Zhang, Lynh Nguyen
Myeloid neoplasm are derived from precursor cells of myeloid lineage and are composed of a broad spectrum of hematopoietic malignancies. The nature of the myeloid precursors is largely under-investigated until the recent application of next generation sequencing (NGS) technology for genome-wide analysis of myeloid neoplasms. It is important to define precursor myeloid neoplasms mediated by molecular signatures including driver gene mutations essential in disease initiation as well as acquired genetic alterations that play a role in disease progression. In addition to myelodysplastic syndrome with a high risk of leukemic transformation, there are newly proposed early precursor disorders with the potential to evolve into myeloid neoplasms [e.g., clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenias of undetermined significance (CCUS)]. Furthermore, certain predisposing germline mutations (e.g. CEBPA, DDX41, RUNX1, ETV6 and GATA) have been recognized with predisposition to develop into myeloid neoplasms. This review paper aims to provide a brief summary of novel concepts of early precursor lesions that could lead to myeloid neoplasms, potential molecular prognostic indicators for MDS, and updated sub-classification of myelodysplastic syndromes according to the 2016 revision of World Health Organization (WHO).
{"title":"Myelodysplastic Syndromes and Other Precursor Myeloid Neoplasms in the Era of Genomic Medicine (Mini Review)","authors":"Ling Zhang, Lynh Nguyen","doi":"10.4172/2329-6917.1000223","DOIUrl":"https://doi.org/10.4172/2329-6917.1000223","url":null,"abstract":"Myeloid neoplasm are derived from precursor cells of myeloid lineage and are composed of a broad spectrum of hematopoietic malignancies. The nature of the myeloid precursors is largely under-investigated until the recent application of next generation sequencing (NGS) technology for genome-wide analysis of myeloid neoplasms. It is important to define precursor myeloid neoplasms mediated by molecular signatures including driver gene mutations essential in disease initiation as well as acquired genetic alterations that play a role in disease progression. In addition to myelodysplastic syndrome with a high risk of leukemic transformation, there are newly proposed early precursor disorders with the potential to evolve into myeloid neoplasms [e.g., clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenias of undetermined significance (CCUS)]. Furthermore, certain predisposing germline mutations (e.g. CEBPA, DDX41, RUNX1, ETV6 and GATA) have been recognized with predisposition to develop into myeloid neoplasms. This review paper aims to provide a brief summary of novel concepts of early precursor lesions that could lead to myeloid neoplasms, potential molecular prognostic indicators for MDS, and updated sub-classification of myelodysplastic syndromes according to the 2016 revision of World Health Organization (WHO).","PeriodicalId":90223,"journal":{"name":"Journal of leukemia (Los Angeles, Calif.)","volume":"4 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2329-6917.1000223","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70269894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：